1. Home
  2. LIEN vs RIGL Comparison

LIEN vs RIGL Comparison

Compare LIEN & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LIEN
  • RIGL
  • Stock Information
  • Founded
  • LIEN 2021
  • RIGL 1996
  • Country
  • LIEN United States
  • RIGL United States
  • Employees
  • LIEN N/A
  • RIGL N/A
  • Industry
  • LIEN
  • RIGL Biotechnology: Pharmaceutical Preparations
  • Sector
  • LIEN
  • RIGL Health Care
  • Exchange
  • LIEN NYSE
  • RIGL Nasdaq
  • Market Cap
  • LIEN 294.4M
  • RIGL 247.1M
  • IPO Year
  • LIEN 2022
  • RIGL 2000
  • Fundamental
  • Price
  • LIEN $12.89
  • RIGL $15.70
  • Analyst Decision
  • LIEN
  • RIGL Buy
  • Analyst Count
  • LIEN 0
  • RIGL 4
  • Target Price
  • LIEN N/A
  • RIGL $31.13
  • AVG Volume (30 Days)
  • LIEN 8.7K
  • RIGL 103.3K
  • Earning Date
  • LIEN 11-08-2024
  • RIGL 11-07-2024
  • Dividend Yield
  • LIEN 7.76%
  • RIGL N/A
  • EPS Growth
  • LIEN 5.69
  • RIGL N/A
  • EPS
  • LIEN 0.90
  • RIGL N/A
  • Revenue
  • LIEN $12,422,942.00
  • RIGL $130,201,000.00
  • Revenue This Year
  • LIEN N/A
  • RIGL $38.26
  • Revenue Next Year
  • LIEN N/A
  • RIGL $24.21
  • P/E Ratio
  • LIEN $14.35
  • RIGL N/A
  • Revenue Growth
  • LIEN 44.81
  • RIGL 7.48
  • 52 Week Low
  • LIEN $7.29
  • RIGL $7.48
  • 52 Week High
  • LIEN $13.38
  • RIGL $17.30
  • Technical
  • Relative Strength Index (RSI)
  • LIEN N/A
  • RIGL 54.17
  • Support Level
  • LIEN N/A
  • RIGL $13.91
  • Resistance Level
  • LIEN N/A
  • RIGL $15.37
  • Average True Range (ATR)
  • LIEN 0.00
  • RIGL 0.53
  • MACD
  • LIEN 0.00
  • RIGL 0.00
  • Stochastic Oscillator
  • LIEN 0.00
  • RIGL 78.13

About LIEN CHICAGO ATLANTIC BDC INC

Chicago Atlantic BDC Inc is a specialty finance company. The company's investment objective is to maximize risk-adjusted returns on equity for its stockholders by investing primarily in direct loans to privately held middle-market companies, with a focus on cannabis companies.

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Share on Social Networks: